Roi Gazit
Overview
Explore the profile of Roi Gazit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
3296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu F, Muskat N, Dvilansky I, Koren O, Shahar A, Gazit R, et al.
Nat Commun
. 2023 Oct;
14(1):6208.
PMID: 37798264
Lysine acetylation has been discovered in thousands of non-histone human proteins, including most metabolic enzymes. Deciphering the functions of acetylation is key to understanding how metabolic cues mediate metabolic enzyme...
2.
Ner-Gaon H, Peleg R, Gazit R, Reiner-Benaim A, Shay T
Front Immunol
. 2023 Sep;
14:1116392.
PMID: 37711610
Most human genes code for more than one transcript. Different ratios of transcripts of the same gene can be found in different cell types or states, indicating differential use of...
3.
Thapa R, Elfassy E, Olender L, Sharabi O, Gazit R
Stem Cell Res Ther
. 2023 Jun;
14(1):152.
PMID: 37280691
Adult hematopoietic stem cells (HSCs) in the bone marrow (BM) are quiescent. Following perturbations, such as blood loss or infection, HSCs may undergo activation. Surprisingly, little is known about the...
4.
5.
Ofir N, Mizrakli Y, Greenshpan Y, Gepner Y, Sharabi O, Tsaban G, et al.
Bone
. 2023 Mar;
171:116727.
PMID: 36898571
Background: Increased levels of bone marrow adipose tissue (BMAT) are negatively associated with skeletal health and hematopoiesis. BMAT is known to increase with age; however, the effect of long-term weight...
6.
Chamo M, Koren O, Goldstein O, Bujanover N, Keinan N, Scharff Y, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765677
Acute Myeloid Leukemia (AML) is a severe disease with a very high relapse rate. AML relapse may be attributable to leukemic stem cells (LSC). Notably, the "cancer stem cell" theory,...
7.
Levy S, Abd Alhadi M, Azulay A, Kahana A, Bujanover N, Gazit R, et al.
Immunol Cell Biol
. 2022 Dec;
101(3):231-248.
PMID: 36567516
Vaccination and natural infection both elicit potent humoral responses that provide protection from subsequent infections. The immune history of an individual following such exposures is in part encoded by antibodies....
8.
Greenshpan Y, Sharabi O, Yegodayev K, Novoplansky O, Elkabets M, Gazit R, et al.
Int J Mol Sci
. 2022 Jul;
23(13).
PMID: 35806439
Harnessing immune effector cells to benefit cancer patients is becoming more and more prevalent in recent years. However, the increasing number of different therapeutic approaches, such as chimeric antigen receptors...
9.
Iraqi M, Edri A, Greenshpan Y, Goldstein O, Ofir N, Bolel P, et al.
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35563109
Multiple Myeloma (MM) is a devastating malignancy that evades immune destruction using multiple mechanisms. The NKp44 receptor interacts with PCNA (Proliferating Cell Nuclear Antigen) and may inhibit NK cells' functions....
10.
Sharabi O, Greenshpan Y, Ofir N, Ottolenghi A, Levi T, Olender L, et al.
Sci Rep
. 2022 May;
12(1):7169.
PMID: 35504918
Cancer immunotherapies are highly potent and are gaining wide clinical usage. However, severe side effects require focusing effector immune cell activities on the tumor microenvironment (TME). We recently developed a...